Clinical Trials Logo

Lip Neoplasms clinical trials

View clinical trials related to Lip Neoplasms.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05512767 Withdrawn - Clinical trials for Head and Neck Carcinoma

A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This clinical trial tests whether adding the use of a pneumatic compression system with manual lymphatic drainage versus manual lymphatic drainage alone in treating patients with lymphedema after chemoradiation for stage II-IV head and neck cancer. Lymphedema can be the result of surgery, radiation therapy, chemotherapy or any combination of these procedures. Internal lymphedema has been shown to negatively affect speech production, swallowing, respiration, and voice. Flexitouch is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides pressure changes to move lymph fluid from the impaired area toward healthy regions of the body. Complete decongestive therapy (CDT) is standard of care for treating external lymphedema and involves manual lymphatic drainage (MLD) performed by licensed therapists followed by compression therapy. CDT has long been used for treating lymphedema of the limbs. Combining a pneumatic compression system with standard of care manual lymphatic drainage may have positive effects on speech, voice, and swallowing.

NCT ID: NCT02915172 Withdrawn - Advanced Cancer Clinical Trials

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Start date: December 2016
Phase: Phase 1
Study type: Interventional

There are 2 phases in this study: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenvatinib and Xeloda (capecitabine) that can be given to patients with advanced cancer. The goal of Phase 2 of this study is to learn if the dose of lenvatinib and capecitabine found in Phase 1 can help to control advanced cancer. The safety of this drug combination will be studied in both phases of the study.

NCT ID: NCT02812056 Withdrawn - Clinical trials for Malignant Neoplasms of Female Genital Organs

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Start date: September 2016
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the combination of alisertib and TAK-228 that can be given to participants with advanced solid tumors that are associated with HPV. Researchers also want to learn if the study drug combination can help to control advanced solid tumors.

NCT ID: NCT00006106 Withdrawn - Clinical trials for Head and Neck Cancer

ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer

Start date: July 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: A specially modified virus called ONYX-015 may be able to kill tumor cells while leaving normal cells undamaged. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining ONYX-015 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of ONYX-015 combined with cisplatin and fluorouracil in treating patients who have advanced head and neck cancer.